A Phase 3 interventional study of Atazanavir Sulphate and Ritonavir in HIV, sponsored by Bristol-Myers Squibb. Completed at 32 sites in 11 countries. Open to participants aged 3 Months to 11 Years. Per ClinicalTrials.gov, last updated 2018-11-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged ≥3 months to \<11 years.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atazanavir powder orally (dosed by weight: 5 to \<10 kg=150 mg, 5 to \<10 kg=200 mg, 10 to \<15 kg=200 mg, 15 to \<25 kg=250 mg, 25 to \<35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to \<25 kg=80 mg, 25 to \<35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to \<35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to \<35 kg=100 mg)
Drug: Atazanavir Sulphate · Drug: Ritonavir
Also known as: Reyataz, BMS-232632
Also known as: Norvir
Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash on ATV Powder
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
Time frame: Day one to week 300 (approximately 22-Jan-2018)
Number of Participants Who Experienced a SAE on ATV Powder
SAE= any of the the following: is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event (defined as a medical event(s) that may not be immediately life threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention \[eg, medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization
Time frame: Day one to week 300 (approximately 22-Jan-2018)
Number of Participants With A Center of Disease Control and Prevention (CDC) Class C AIDS Event on ATV Powder
The CDC disease staging system assesses the severity of HIV disease by CD4 cell counts and by the presence of specific HIV-related conditions. CD4 counts are classified as 1: ≥500 cells/µL, 2: 200-499 cells/µL, and 3: \<200 cells/µL. Children with HIV infection are also classified in each of several categories. Category N: Not symptomatic. Category A: Mildly symptomatic. Category B: Moderately symptomatic. Category C: Severely symptomatic.
Time frame: Day one to week 300 (approximately 22-Jan-2018)
Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality on ATV Powder
Criteria of the Division of AIDS for grading the severity of adult and pediatric adverse events as follows: Grade (Gr) 1=mild; Gr 2=moderate; Gr 3=severe; Gr 4=potentially life-threatening. Neutrophils (absolute) (adult and infants \>7 days): Gr 1=1.000-1300/mm\^3; Gr 2=750-999 mm\^3; Gr 3=500-749 mm\^3; Gr 4= \<500 mm\^3. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase: Gr 1=1.25-2.5\*upper limit of normal (ULN); Gr 2=2.6-5.0\*ULN; Gr 3=5.1-10.0\*ULN; Gr 4= \>10.0\*ULN. Bilirubin, total (adults and infants \>14 days): Gr 1=1.1-1.5\*ULN; Gr 2=1.6-2.5\*ULN; Gr 3=2.6-5.0\*ULN; Gr 4= \>5.0\*ULN. Lipase: Gr 1=1.1-1.5\*ULN; Gr 2=1.6-3.0\*ULN; Gr 3=3.1-5.0\*ULN; Gr 4= \>5.0\*ULN. Bicarbonate, serum low: Gr 1=16.0 mEq/L-\<lower limit of normal; Gr 2=11.0-15.9 mEq/L; Gr 3=8.0-10.9 mEq/L; Gr 4= \<8 mEq/L. By criteria of the World Health Organization: Amylase: Gr 1=1.0-1.39\*ULN; Gr 2=1.40-2.09\*ULN; Gr 3.=2.10-5.0\*ULN; Gr 4= \>5.0\*ULN.
Time frame: Day one to week 300 (approximately 22-Jan-2018)
Number of Participants With HIV RNA <50 Copies/mL and <400 Copies/mL in the Week 24 Atazanavir Powder Cohort and the Eligible Week 48 Atazanavir Powder Cohort
Virologic success includes patients with HIV RNA \<50 copies/mL. Two cohorts were assessed: The Atazanavir Powder Cohort=patients who received treatment and did not switch to capsule before analysis Week 24 or before their HIV RNA Week 24 assessment, and the Eligible Week 48 Atazanavir Powder Cohort=patients who initiated study treatment at least 48 weeks before last person last visit and did not switch to capsule before analysis Week 48 or before their HIV RNA Week 48 assessment.
Time frame: Day 1 of treatment to weeks 24 and 48
Mean Change From Baseline in HIV RNA on ATV Powder
Human immunodeficiency virus ribonucleic acid (HIV RNA) change from baseline using observed values
Time frame: Baseline to Weeks 24 and 48
Mean Change From Baseline in CD4 Percent on ATV Powder
Change in CD4 percent using observed values
Time frame: Baseline to Weeks 24 and 48
CD4 Cell Count Changes From Baseline on ATV Powder
CD4 cell count change from baseline using observed values
Time frame: Baseline to Weeks 24 and 48
Number of Participants With Emergent Genotypic Substitutions on ATV Powder Through Week 48
Newly emergent substitutions are on-treatment substitutions that were not detected at baseline.Viral rebound in the resistance analysis was defined as: Less than a 1 log10 drop from baseline in plasma HIV RNA level by Week 16, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, a plasma HIV RNA level \>200 c/mL after Week 24, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, repeated plasma HIV RNA level ≥50 c/mL after Week 48. Viral rebound was defined as a plasma HIV RNA level ≥400 c/mL at any time in a patient who had previously achieved a plasma HIV RNA level \<50 c/mL. Or, a plasma HIV RNA level ≥50 c/mL and \<1,000 c/mL followed by a return to virologic suppression was considered a viral blip and not a viral rebound. NRTI=nucleoside reverse transcriptase inhibitor
Time frame: Baseline through Week 48
Maximum Observed Plasma Concentration (Cmax)
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmax
Time frame: Baseline to Week 2
Minimum Plasma Concentration (Cmin)
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmin
Time frame: Baseline to Week 2
Area Under the Concentration-Time Curve [AUC(TAU)]
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV AUC
Time frame: Baseline to Week 2
| Milestone | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Started | 23 | 12 | 21 | 35 | 8 |
| Completed | 15 | 4 | 16 | 26 | 6 |
| Not completed | 8 | 8 | 5 | 9 | 2 |
| Withdrew: Lack of efficacy | 3 | 1 | 3 | 3 | 1 |
| Withdrew: Adverse event | 1 | 2 | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Poor compliance/noncompliance | 0 | 1 | 0 | 2 | 0 |
| Withdrew: No longer meets study criteria | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 1 | 0 |
| Milestone | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Started | 15 | 4 | 16 | 26 | 6 |
| Completed | 4 | 1 | 11 | 18 | 5 |
| Not completed | 11 | 3 | 5 | 8 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 3 | 1 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 1 | 0 | 0 |
| Withdrew: Poor compliance/noncompliance | 1 | 0 | 1 | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Capsules received at state hospital | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Switched to another formulation | 1 | 1 | 0 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
| Participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 |
| AEs leading to discontinuation | 3 | 2 | 2 | 2 | 1 |
| Hyperbilirubinemia related adverse events | 2 | 0 | 9 | 7 | 0 |
| Jaundice | 0 | 0 | 3 | 3 | 0 |
| Atrioventricular block, first degree | 0 | 0 | 0 | 1 | 0 |
| Tachycardia | 0 | 0 | 1 | 0 | 0 |
| Rash | 3 | 0 | 4 | 5 | 1 |
SAE= any of the the following: is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event (defined as a medical event(s) that may not be immediately life threatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention \[eg, medical, surgical\] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization
| participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a SAE on ATV Powder | 6 | 3 | 8 | 8 | 0 |
The CDC disease staging system assesses the severity of HIV disease by CD4 cell counts and by the presence of specific HIV-related conditions. CD4 counts are classified as 1: ≥500 cells/µL, 2: 200-499 cells/µL, and 3: \<200 cells/µL. Children with HIV infection are also classified in each of several categories. Category N: Not symptomatic. Category A: Mildly symptomatic. Category B: Moderately symptomatic. Category C: Severely symptomatic.
| Participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Pulmonary tuberculosis | 2 | 0 | 1 | 0 | 0 |
| Lymph node tuberculosis | 0 | 0 | 0 | 1 | 0 |
| Tuberculosis | 0 | 0 | 0 | 1 | 0 |
| Oropharyngeal Candidiasis | 1 | 0 | 0 | 0 | 0 |
Criteria of the Division of AIDS for grading the severity of adult and pediatric adverse events as follows: Grade (Gr) 1=mild; Gr 2=moderate; Gr 3=severe; Gr 4=potentially life-threatening. Neutrophils (absolute) (adult and infants \>7 days): Gr 1=1.000-1300/mm\^3; Gr 2=750-999 mm\^3; Gr 3=500-749 mm\^3; Gr 4= \<500 mm\^3. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase: Gr 1=1.25-2.5\*upper limit of normal (ULN); Gr 2=2.6-5.0\*ULN; Gr 3=5.1-10.0\*ULN; Gr 4= \>10.0\*ULN. Bilirubin, total (adults and infants \>14 days): Gr 1=1.1-1.5\*ULN; Gr 2=1.6-2.5\*ULN; Gr 3=2.6-5.0\*ULN; Gr 4= \>5.0\*ULN. Lipase: Gr 1=1.1-1.5\*ULN; Gr 2=1.6-3.0\*ULN; Gr 3=3.1-5.0\*ULN; Gr 4= \>5.0\*ULN. Bicarbonate, serum low: Gr 1=16.0 mEq/L-\<lower limit of normal; Gr 2=11.0-15.9 mEq/L; Gr 3=8.0-10.9 mEq/L; Gr 4= \<8 mEq/L. By criteria of the World Health Organization: Amylase: Gr 1=1.0-1.39\*ULN; Gr 2=1.40-2.09\*ULN; Gr 3.=2.10-5.0\*ULN; Gr 4= \>5.0\*ULN.
| Participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Neutrophils (absolute) | 0 | 0 | 4 | 6 | 0 |
| Alanine aminotransferase | 4 | 1 | 1 | 2 | 0 |
| Aspartate aminotransferase | 2 | 0 | 1 | 0 | 0 |
| Alkaline phosphatase | 1 | 2 | 1 | 0 | 0 |
| Total bilirubin | 4 | 1 | 10 | 5 | 2 |
| Amylase | 15 | 7 | 6 | 6 | 1 |
| Lipase | 3 | 2 | 0 | 2 | 1 |
| Bicarbonate | 2 | 0 | 0 | 0 | 0 |
| Albumin | 1 | 1 | 0 | 1 | 0 |
| Calcium, High | 0 | 0 | 0 | 1 | 0 |
| Chloride, Low | 0 | 0 | 0 | 1 | 0 |
| Total Cholesterol, Fasting | 0 | 0 | 1 | 0 | 0 |
| LDL Cholesterol, Fasting | 0 | 0 | 1 | 0 | 0 |
| Glucose, Fasting, Low | 0 | 0 | 1 | 0 | 0 |
Virologic success includes patients with HIV RNA \<50 copies/mL. Two cohorts were assessed: The Atazanavir Powder Cohort=patients who received treatment and did not switch to capsule before analysis Week 24 or before their HIV RNA Week 24 assessment, and the Eligible Week 48 Atazanavir Powder Cohort=patients who initiated study treatment at least 48 weeks before last person last visit and did not switch to capsule before analysis Week 48 or before their HIV RNA Week 48 assessment.
| Participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Week 24: HIV RNA<50 copies/mL | 10 | 2 | 10 | 19 | 5 |
| Week 24: HIV RNA<400 copies/mL | 15 | 5 | 15 | 24 | 6 |
| Week 48: HIV RNA<50 copies/mL | 11 | 0 | 6 | 18 | 1 |
| Week 48:HIV RNA<400 copies/mL | 14 | 1 | 14 | 22 | 1 |
Human immunodeficiency virus ribonucleic acid (HIV RNA) change from baseline using observed values
| Log copies per millileter | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Week 24 | -2.10 ± 0.2863 | -3.07 ± 0.4780 | -2.69 ± 0.2257 | -2.66 ± 0.1550 | -2.24 ± 0.3821 |
| Week 48 | -2.31 ± 0.3174 | -4.06 ± 0.1649 | -2.91 ± 0.1883 | -2.70 ± 0.1269 | -3.97 ± NA |
Change in CD4 percent using observed values
| Percent Change | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Week 24 | 5.1 ± 1.521 | 4.0 ± 1.581 | 5.4 ± 2.448 | 6.3 ± 1.280 | -0.3 ± 4.349 |
| Week 48 | 2.8 ± 3.167 | — | 8.9 ± 2.182 | 7.5 ± 1.825 | 1.0 ± NA |
CD4 cell count change from baseline using observed values
| Cells/mm^3 | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Week 24 | 218.7 ± 259.102 | 67.8 ± 425.659 | 247.1 ± 110.739 | 246.1 ± 72.044 | 145.8 ± 78.443 |
| Week 48 | -409.8 ± 437.686 | — | 400.0 ± 156.021 | 335.4 ± 108.925 | 213.0 ± NA |
Newly emergent substitutions are on-treatment substitutions that were not detected at baseline.Viral rebound in the resistance analysis was defined as: Less than a 1 log10 drop from baseline in plasma HIV RNA level by Week 16, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, a plasma HIV RNA level \>200 c/mL after Week 24, confirmed by a second plasma HIV RNA level redrawn within 2 and 4 weeks from original sample. Or, repeated plasma HIV RNA level ≥50 c/mL after Week 48. Viral rebound was defined as a plasma HIV RNA level ≥400 c/mL at any time in a patient who had previously achieved a plasma HIV RNA level \<50 c/mL. Or, a plasma HIV RNA level ≥50 c/mL and \<1,000 c/mL followed by a return to virologic suppression was considered a viral blip and not a viral rebound. NRTI=nucleoside reverse transcriptase inhibitor
| Participants | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|---|---|
| Any PI substitutions | 4 | 0 | 4 | 3 | 0 |
| Any IAS-USA PI substitutions | 1 | 0 | 2 | 0 | 0 |
| Any select RT substitutions | 2 | 1 | 2 | 1 | 0 |
| NRTI | 1 | 1 | 2 | 1 | 0 |
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmax
| ng/mL | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 5776.70 ± 3417.208 | 5644.12 ± 3093.516 | 4893.75 ± 2523.959 |
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV Cmin
| ng/mL | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|
| Minimum Plasma Concentration (Cmin) | 718.90 ± 432.747 | 857.06 ± 599.221 | 1030.64 ± 1070.932 |
To describe the PK profile of ATV powder formulation with RTV in pediatric subjects weighing 25 - \< 35 kg and/or 6 to \< 11 years of age and for the new 5 - \< 10 kg cohort (200 mg ATV and 80 mg RTV) in terms of ATV AUC
| ng.h./mL | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) |
|---|---|---|---|
| Area Under the Concentration-Time Curve [AUC(TAU)] | 49387.12 ± 26890.782 | 59671.80 ± 31706.655 | 56356.00 ± 35233.024 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/L Weight 5 to lt 10kg (ATV 150mg) | 0/23 (0%) | 6/23 (26.1%) | 22/23 (95.7%) |
| B/L Weight 5 to lt 10kg (ATV 200mg) | 0/12 (0%) | 3/12 (25%) | 10/12 (83.3%) |
| B/L Weight 10 to lt 15kg | 0/21 (0%) | 8/21 (38.1%) | 19/21 (90.5%) |
| B/L Weight 15 to lt 25kg | 0/35 (0%) | 10/35 (28.6%) | 31/35 (88.6%) |
| B/L Weight 25 to lt 35kg | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | B/L Weight 5 to lt 10kg (ATV 150mg) | B/L Weight 5 to lt 10kg (ATV 200mg) | B/L Weight 10 to lt 15kg | B/L Weight 15 to lt 25kg | B/L Weight 25 to lt 35kg |
|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/23 | 1/12 | 1/21 | 0/35 | 0/8 |
| PertussisInfections and infestations | 0/23 | 1/12 | 0/21 | 0/35 | 0/8 |
| Pulmonary tuberculosisInfections and infestations | 0/23 | 1/12 | 0/21 | 0/35 | 0/8 |
| Pneumonitis chemicalInjury, poisoning and procedural complications | 0/23 | 1/12 | 0/21 | 0/35 | 0/8 |
| OverdoseInjury, poisoning and procedural complications | 0/23 | 0/12 | 0/21 | 2/35 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/23 | 0/12 | 1/21 | 2/35 | 0/8 |
| LymphadenopathyBlood and lymphatic system disorders | 0/23 | 0/12 | 1/21 | 0/35 | 0/8 |
| VomitingGastrointestinal disorders | 0/23 | 0/12 | 1/21 | 0/35 | 0/8 |
| DysenteryInfections and infestations | 1/23 | 0/12 | 1/21 | 0/35 | 0/8 |
| Infective corneal ulcerInfections and infestations | 0/23 | 0/12 | 1/21 | 0/35 | 0/8 |
| Event | B/L Weight 5 to lt 10kg (ATV 150mg) | B/L Weight 5 to lt 10kg (ATV 200mg) | B/L Weight 10 to lt 15kg | B/L Weight 15 to lt 25kg | B/L Weight 25 to lt 35kg |
|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 16/23 | 5/12 | 5/21 | 10/35 | 2/8 |
| GastroenteritisInfections and infestations | 14/23 | 3/12 | 11/21 | 8/35 | 2/8 |
| Lower respiratory tract infectionInfections and infestations | 7/23 | 5/12 | 1/21 | 1/35 | 1/8 |
| Oral candidiasisInfections and infestations | 9/23 | 4/12 | 1/21 | 0/35 | 0/8 |
| PyrexiaGeneral disorders | 3/23 | 0/12 | 8/21 | 4/35 | 3/8 |
| NasopharyngitisInfections and infestations | 2/23 | 0/12 | 8/21 | 6/35 | 0/8 |
| VomitingGastrointestinal disorders | 7/23 | 1/12 | 6/21 | 9/35 | 3/8 |
| AnaemiaBlood and lymphatic system disorders | 8/23 | 2/12 | 0/21 | 2/35 | 0/8 |
| Candida nappy rashInfections and infestations | 8/23 | 2/12 | 1/21 | 0/35 | 0/8 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 5/23 | 4/12 | 0/21 | 4/35 | 0/8 |
All participants who received at least 1 dose of study drug
| Age, Continuous(Months) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| Mean | 8.4 ± 6.42 | 10.5 ± 9.21 | 37.4 ± 12.44 | 67.2 ± 16.70 | 93.4 ± 15.53 | 42.5 ± 31.58 |
| Sex: Female, Male(Participants) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 6 | 12 | 18 | 3 | 51 |
| Male | 11 | 6 | 9 | 17 | 5 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 2 | 1 | 0 | 4 |
| Not Hispanic or Latino | 1 | 1 | 1 | 1 | 0 | 4 |
| Unknown or Not Reported | 22 | 10 | 18 | 33 | 8 | 91 |
| Race/Ethnicity, Customized(Participants) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| White | 2 | 2 | 12 | 13 | 3 | 32 |
| Black/African American | 19 | 6 | 7 | 20 | 5 | 57 |
| Other | 2 | 4 | 2 | 2 | 0 | 10 |
| Region of Enrollment(Participants) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| North America | 2 | 1 | 9 | 4 | 2 | 18 |
| South America | 1 | 1 | 1 | 4 | 1 | 8 |
| Africa | 20 | 10 | 8 | 21 | 5 | 64 |
| Europe | 0 | 0 | 3 | 6 | 0 | 9 |
| Country(Participants) | Atazanavir, 150 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 5 to <10 kg) | Atazanavir, 200 mg + Ritonavir, 80 mg (Weight: 10 to <15 kg) | Atazanavir, 250 mg + Ritonavir, 80 mg (Weight: 15 to <25 kg) | Atazanavir, 300 mg + Ritonavir, 100 mg (Weight: 25 to <35 kg) | Total |
|---|---|---|---|---|---|---|
| Argentina | 0 | 1 | 1 | 2 | 0 | 4 |
| Brazil | 0 | 0 | 0 | 1 | 0 | 1 |
| Chile | 1 | 0 | 0 | 1 | 1 | 3 |
| Mexico | 1 | 1 | 7 | 4 | 2 | 15 |
| Poland | 0 | 0 | 1 | 0 | 0 | 1 |
| Romania | 0 | 0 | 0 | 1 | 0 | 1 |
| Russia | 0 | 0 | 1 | 3 | 0 | 4 |
| South Africa | 20 | 10 | 8 | 21 | 5 | 64 |
| Spain | 0 | 0 | 1 | 2 | 0 | 3 |
| United States | 1 | 0 | 2 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2011 to primary completion in Sep 2014, 39 months.
Results were first posted in Feb 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ritonavir